Treat-to-Target in Inflammatory Bowel Disease: Promise, Perils, and the Path Forward
Clinical Gastroenterology and Hepatology · 2026-10
DOI: 10.1016/j.cgh.2026.09.033 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-10. Verfasst von Siddharth Singh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona. Electronic address: singh.siddharth@ma…. Die Arbeit nennt 43 Literaturangaben. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Treat-to-target has become the organizing framework for contemporary inflammatory bowel disease (IBD) management, yet its evidence base is less robust than its widespread endorsement might suggest. The approach rests on 2 equally essential pillars: defining the right therapeutic target and adjusting treatment iteratively until that target is achieved. Over the past decade, the first pillar has advanced substantially: targets have deepened from symptomatic remission through endoscopic and histologic healing toward transmural and emerging molecular end points, supported largely by association data linking deeper remission to better long-term outcomes. The second pillar has received considerably less scrutiny. Completed randomized trials of iterative treatment adjustment have yielded mixed results in unselected populations, real-world monitoring remains inconsistent, and the most clinically pressing question, whether asymptomatic patients with residual inflammation benefit from optimizing or switching advanced therapies, remains unanswered. In this review, we critically examine both pillars: the evolution and evidence base for treatment targets in IBD, the ability of current therapies to achieve them, the lessons from pivotal treat-to-target trials, and the barriers to real-world implementation. We propose a framework for individualizing treat-to-target decisions based on disease history, inflammatory trajectory, therapeutic options, and patient preferences. Ongoing trials including QUOTIENT, VERDICT, and VECTORS may define whether the second pillar can be placed on as firm a footing as the first.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona. Electronic address: singh.siddharth@mayo.edu.
- Gastroenterology Unit, Department of Public Health, University of Naples Federico II, Naples, Italy.
- IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, Milan, Italy; Medicine and Surgery Department, Vita-Salute San Raffaele University, Milan, Italy.
- Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada.
- Mater Research Institute, Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.
- Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas; Section of Gastroenterology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Singh, S., Nardone, O. M., Allocca, M., Yuan, Y., Begun, J., Hou, J. K., Shehab, M., Kobayashi, T., Ahuja, V., Dignass, A., & Jairath, V. (2026). Treat-to-Target in Inflammatory Bowel Disease: Promise, Perils, and the Path Forward. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.09.033
Vancouver
Singh S, Nardone OM, Allocca M, Yuan Y, Begun J, Hou JK, et al. Treat-to-Target in Inflammatory Bowel Disease: Promise, Perils, and the Path Forward. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.09.033
BibTeX
@article{Singh2026,
author = {Singh, Siddharth and Nardone, Olga Maria and Allocca, Mariangela and Yuan, Yuhong and Begun, Jakob and Hou, Jason K and Shehab, Mohammad and Kobayashi, Taku and Ahuja, Vineet and Dignass, Axel and Jairath, Vipul},
title = {Treat-to-Target in Inflammatory Bowel Disease: Promise, Perils, and the Path Forward},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
doi = {10.1016/j.cgh.2026.09.033}
}
EUVIMED